1228.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 birž. 2024 @ 09:05):
Our systems believe the stock currently is overvalued by -1.50% compare to its pairs and should correct downwards.

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide...

Stats
Dzisiejszy wolumen	21 000
Średni wolumen	69 394
Kapitalizacja rynkowa	140.20M
EPS	HKD-0.190 ( Q4 \| 2023-12-31 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-0.340 (Sector) 14.27 (Industry) 6.31
ATR14	HKD0 (0.00%)

0690.HK -1.54%

1061.HK -0.82%

1167.HK 1.32%

1177.HK 0.00%

1228.HK 0.00%

1477.HK -0.30%

1521.HK -1.22%

1530.HK -1.12%

1548.HK -1.18%

1672.HK -3.61%

1873.HK 0.00%

1875.HK -0.91%

1877.HK -1.70%

1952.HK -1.29%

2096.HK -1.39%

2126.HK -3.50%

2137.HK -2.94%

2142.HK -1.47%

2157.HK -2.45%

2162.HK -4.75%

2171.HK -3.06%

2179.HK -3.00%

2197.HK 1.45%

2256.HK 3.67%

2257.HK 3.50%

2616.HK 1.80%

2696.HK -1.09%

3759.HK -0.93%

6160.HK 1.12%

6600.HK 0.86%

6622.HK 0.71%

6628.HK 2.00%

6821.HK 0.51%

6826.HK 2.24%

6978.HK 2.88%

6996.HK 0.00%

6998.HK -1.75%

9688.HK -0.30%

9926.HK -2.85%

9939.HK -2.75%

9966.HK -0.83%

9969.HK 4.30%

9995.HK -4.28%

Korelacja (AI algo v.1.1b): Overvalued: -1.50% HKD0.330 paired level. (Algorytm śledzi zmiany najbardziej skorelowanych akcji w czasie rzeczywistym i natychmiast aktualizuje)

CANbridge Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CANbridge Pharmaceuticals Finanse

Annual	2023
Przychody:	HKD102.87M
Zysk brutto:	HKD64.16M (62.37 %)
EPS:	HKD-0.890

FY	2023
Przychody:	HKD102.87M
Zysk brutto:	HKD64.16M (62.37 %)
EPS:	HKD-0.890

FY	2022
Przychody:	HKD78.97M
Zysk brutto:	HKD48.89M (61.91 %)
EPS:	HKD-1.140

Financial Reports:

No articles found.

CANbridge Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

CANbridge Pharmaceuticals

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.